RESULTS OF HEART-LUNG TRANSPLANTATION IN CHILDREN WITH CYSTIC-FIBROSIS

被引：18

作者：

WHITEHEAD, BF

REES, PG

SORENSEN, K

BULL, C

FABRE, J

DELEVAL, MR

ELLIOTT, MJ

机构：

[1] Cardiothoracic Unit, The Hospital for Sick Children, London, WC1N 3JH, Great Ormond Street

[2] The Institute of Child Health, University of London, London

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1995年 / 9卷 / 01期

关键词：

CYSTIC FIBROSIS; CHILDREN; HEART-LUNG TRANSPLANTATION; OBLITERATIVE BRONCHIOLITIS;

D O I：

10.1016/S1010-7940(05)80040-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Children with cystic fibrosis represent the largest group referred for, and undergoing, heart-lung transplantation at our institute. Between June 1988 and July 1993, 76 patients were accepted for transplantation, of whom 25 were transplanted, while a further 36 died waiting. Those transplanted ranged from 5-18 years of age and included 13 males and 12 females. Organs were used from donors matched by ABO blood group, size and cytomegalovirus (CMV) status. Post-transplant maintenance immunosuppression comprised cyclosporin A, azathioprine and prednisolone. Anti-thymocyte globulin and high dose methylprednisolone were given peri-operatively and for acute rejection episodes. Acturial survival was 67% at 1 year, 61% at 2 years and 54% at 3 years. Obliterative bronchiolitis (OB) has occurred in 13 patients (52%) and was the major cause of mortality and morbidity. In three patients, OB was associated with the development of tracheal anastomotic stenosis. Other complications included diabetes mellitus (n = 9), pancreatitis (n = 1) and hypertension (n = 8). Despite these problems, those surviving the first year post-transplant showed a mean FEV1 of 71% (compared to 29% pre-transplant) and enjoyed an overall improved quality of life.

引用

页码：1 / 6

页数：6

共 39 条

[1]

Balaji S., Whitehead B., Elliott M.J., De Leval M.R., Pseudoaneurysm of the aorta after heart-lung transplantation: Diagnosis by color flow Doppler mapping, J Heart Lung Transplant, 11, pp. 160-163, (1992)

[2]

Borei J.F., Kis Z.L., The discovery and development of cyclosporine (Sandimmune), Trans Proc, 23, pp. 1867-1874, (1991)

[3]

Burke C.M., Glanville A.R., Macoviak J.A., O'connell B.M., Taze-Laar H.D., Baldwin J.C., Jamieson S.W., Theodore J., The spectrum of cytomegalovirus infection following human heart-lung transplantation, J Heart Transplant, 5, pp. 267-272, (1986)

[4]

Cary N., Moody J., Yannoutsos N., Wallwork J., White D., Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice

[5]

a potential approach to inhibition of hyperacute xenograft rejection, Trans Proc, 25, pp. 400-401, (1993)

[6]

Cooper J.D., Dominoes - pragmatism or piracy? Editorial, Transplant Int, 4, (1991)

[7]

Coutelle C., Caplen N., Hart S., Huxley C., Williamson R., Gene therapy for cystic fibrosis, Arch Dis Child, 68, pp. 437-443, (1993)

[8]

De Leval M.R., Smyth R., Whitehead B., Scott J.P., Elliott M.J., Sharpies L., Caine N., Helms P., Martin I.R., Higenbottam T., Wallwork J., Heart and lung transplantation for terminal cystic fibrosis. A 41/2-year experience, J Thorac Cardiovasc Surg, 101, pp. 633-642, (1991)

[9]

Dunn J., Golden D., Van Buren C.T., Lewis R.M., Lawen J., Kahan B.D., Causes of graft loss beyond two years in the cyclosporine era, Transplantation, 49, pp. 349-353, (1990)

[10]

Hakim M., Higenbottam T.W., Bethune D., Cory-Pearce R., English T., Kneeshaw J., Wells F.C., Wallwork J., Selection and procurement of combined heart and lung grafts for transplantation, J Thorac Cardiovasc Surg, 95, pp. 474-479, (1988)

← 1 2 3 4 →